美国 · SEC FORM 4
Olema Pharmaceuticals, Inc.
OLMA · Nasdaq · CIK 0001750284 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
2 同一窗口内观察到的 Form 4 交易行
2 sales · 0 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-01-08 · Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P. · $1.7M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出较低
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Harmon CyrusDirector
▼▼
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-01-08 · Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P..
近期 Form 4 活动
0买入
25卖出
19其他 Form 4 交易行
15SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出2 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 14,696,219
- 上期报告
- 16,068,469
- 日均成交量
- 1,441,960
- 回补天数
- 10.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-01-08 | Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P. | 买入 (P) | Common Stock | 300,000 | USD 5.76 | USD 1,728,000 | SEC 申报 ↗ |
| 2024-12-17 | Graham G. Walmsley | 买入 (P) | Common Stock | 700,761 | USD 6.75 | USD 4,730,137 | SEC 申报 ↗ |
| 2024-12-13 | Graham G. Walmsley | 买入 (P) | Common Stock | 700,761 | USD 6.75 | USD 4,730,137 | SEC 申报 ↗ |
| 2023-12-06 | Asefaw Senai; Paradigm BioCapital Advisors GP LLC; Paradigm BioCapital International Fund Ltd.; Paradigm Biocapital Advisors LP | 买入 (P) | Common Stock, par value $0.0001 per share | 100,000 | USD 11.60 | USD 1,160,000 | SEC 申报 ↗ |
| 2023-12-05 | Graham G. Walmsley | 买入 (P) | Common Stock | 131,870 | USD 14.19 | USD 1,871,445 | SEC 申报 ↗ |
| 2023-09-12 | Graham G. Walmsley | 买入 (P) | Common Stock | 508,130 | USD 9.84 | USD 4,999,999 | SEC 申报 ↗ |
| 2023-09-12 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common stock, $0.0001 par value | 1,505,932 | USD 9.84 | USD 14,818,371 | SEC 申报 ↗ |
| 2023-04-06 | Kovacs Shane William Charles | 买入 (P) | Common Stock | 10,000 | USD — | USD — | SEC 申报 ↗ |
| 2022-09-21 | Bohen Sean | 买入 (P) | Common Stock | 20,000 | USD — | USD — | SEC 申报 ↗ |
| 2022-09-02 | Kovacs Shane William Charles | 买入 (P) | Common Stock | 20,000 | USD — | USD — | SEC 申报 ↗ |
| 2022-06-10 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common stock, $0.0001 par value | 200,000 | USD 4.03 | USD 806,000 | SEC 申报 ↗ |
| 2021-11-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common stock, $0.0001 par value | 739,675 | USD 9.39 | USD 6,945,548 | SEC 申报 ↗ |
| 2020-11-23 | Graham G. Walmsley | 买入 (P) | Common Stock | 1,160,000 | USD 19.00 | USD 22,040,000 | SEC 申报 ↗ |
| 2020-11-23 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP | 买入 (P) | Common Stock | 425,000 | USD 19.00 | USD 8,075,000 | SEC 申报 ↗ |
| 2020-11-19 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common stock, $0.0001 par value | 1,135,334 | USD 19.00 | USD 21,571,346 | SEC 申报 ↗ |
Form 4 申报证据
44 transaction lines in the latest 365-day window; 253 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | Harmon Cyrus | 卖出 (S) | Common Stock | 12,500 | USD 11.71 | USD 146,375 | SEC 申报 ↗ |
| 2026-07-23 | Harmon Cyrus | 卖出 (S) | Common Stock | 12,500 | USD 11.58 | USD 144,750 | SEC 申报 ↗ |
| 2026-03-04 | Mitchell Shawnte | 卖出 (S) | Comon Stock | 233 | USD 24.69 | USD 5,753 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | Harmon Cyrus | 卖出 (S) | Common Stock | 12,500 | USD 11.71 | USD 146,375 | SEC 申报 ↗ |
| 2026-07-23 | Harmon Cyrus | 卖出 (S) | Common Stock | 12,500 | USD 11.58 | USD 144,750 | SEC 申报 ↗ |
| 2026-03-04 | Mitchell Shawnte | 卖出 (S) | Comon Stock | 233 | USD 24.69 | USD 5,753 | SEC 申报 ↗ |
| 2026-03-04 | Mitchell Shawnte | 卖出 (S) | Common Stock | 24,767 | USD 24.25 | USD 600,600 | SEC 申报 ↗ |
| 2026-03-04 | Mitchell Shawnte | 期权行权／转换 (M) | Common Stock | 25,000 | USD 4.37 | USD 109,250 | SEC 申报 ↗ |
| 2026-03-03 | Mitchell Shawnte | 卖出 (S) | Common Stock | 15,000 | USD 23.01 | USD 345,150 | SEC 申报 ↗ |
| 2026-03-03 | Mitchell Shawnte | 期权行权／转换 (M) | Common Stock | 15,000 | USD 4.37 | USD 65,550 | SEC 申报 ↗ |
| 2026-02-02 | Austin Sasha Lu | 奖励／授予 (A) | Common Stock | 11,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-20 | Harmon Cyrus | 卖出 (S) | Common Stock | 10,000 | USD 26.88 | USD 268,800 | SEC 申报 ↗ |
| 2026-01-15 | Kovacs Shane William Charles | 卖出 (S) | Common Stock | 100,000 | USD 28.73 | USD 2,873,000 | SEC 申报 ↗ |
| 2026-01-14 | Harmon Cyrus | 卖出 (S) | Common Stock | 3,489 | USD 29.12 | USD 101,600 | SEC 申报 ↗ |
| 2026-01-14 | Myles David C. | 卖出 (S) | Common Stock | 50,000 | USD 28.87 | USD 1,443,651 | SEC 申报 ↗ |
| 2026-01-14 | Myles David C. | 期权行权／转换 (M) | Common Stock | 50,000 | USD 4.87 | USD 243,500 | SEC 申报 ↗ |
| 2026-01-13 | Kovacs Shane William Charles | 卖出 (S) | Common Stock | 3,822 | USD 28.01 | USD 107,054 | SEC 申报 ↗ |
| 2026-01-13 | Myles David C. | 卖出 (S) | Common Stock | 50,000 | USD 27.60 | USD 1,380,178 | SEC 申报 ↗ |
| 2026-01-13 | Myles David C. | 期权行权／转换 (M) | Common Stock | 50,000 | USD 4.87 | USD 243,500 | SEC 申报 ↗ |
| 2026-01-12 | Myles David C. | 卖出 (S) | Common Stock | 10,000 | USD 28.34 | USD 283,400 | SEC 申报 ↗ |
| 2025-12-26 | Bohen Sean | 赠与 (G) | Common Stock | 8,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-23 | Zojwalla Naseem | 卖出 (S) | Common Stock | 99,509 | USD 27.66 | USD 2,752,419 | SEC 申报 ↗ |
| 2025-12-23 | Zojwalla Naseem | 期权行权／转换 (M) | Common Stock | 50,000 | USD 7.02 | USD 351,000 | SEC 申报 ↗ |
| 2025-12-22 | Harmon Cyrus | 卖出 (S) | Common Stock | 2,881 | USD 28.53 | USD 82,195 | SEC 申报 ↗ |
| 2025-12-22 | Zojwalla Naseem | 卖出 (S) | Common Stock | 100,000 | USD 28.04 | USD 2,804,000 | SEC 申报 ↗ |
| 2025-12-22 | Zojwalla Naseem | 期权行权／转换 (M) | Common Stock | 50,000 | USD 14.07 | USD 703,392 | SEC 申报 ↗ |
| 2025-12-19 | Zojwalla Naseem | 卖出 (S) | Common Stock | 70,000 | USD 28.20 | USD 1,973,729 | SEC 申报 ↗ |
| 2025-12-19 | Zojwalla Naseem | 期权行权／转换 (M) | Common Stock | 40,000 | USD 15.25 | USD 610,000 | SEC 申报 ↗ |
| 2025-12-19 | Myles David C. | 卖出 (S) | Common Stock | 51,000 | USD 30.46 | USD 1,553,544 | SEC 申报 ↗ |
| 2025-12-19 | Myles David C. | 赠与 (G) | Common Stock | 9,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | CLARK IAN T | 卖出 (S) | Common Stock | 264,800 | USD 29.73 | USD 7,873,109 | SEC 申报 ↗ |
| 2025-12-19 | CLARK IAN T | 期权行权／转换 (M) | Common Stock | 264,800 | USD 4.61 | USD 1,220,382 | SEC 申报 ↗ |
| 2025-12-08 | Kovacs Shane William Charles | 赠与 (G) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | OLMA |
| CIK | 0001750284 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 253 transaction lines from 2020-06-15 to 2026-07-24 24 P purchase lines · 131 S sale lines · 98 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.